Carrier Screening and Diagnosis for Spinal Muscular Atrophy Using Droplet Digital PCR Versus MLPA: Analytical Validation and Early Test Outcome

Dolat Singh Shekhawat,Siyaram Didel,Shilpi Gupta Dixit,Pratibha Singh,Kuldeep Singh
DOI: https://doi.org/10.1089/gtmb.2023.0073
IF: 1.736
2024-03-27
Genetic Testing and Molecular Biomarkers
Abstract:<b><i>Background:</i></b> Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular life-threatening disorder. Owing to high carrier frequency, population-wide SMA screening to quantify the copy number of <i>SMN</i> gene is recommended by American College of Medical Genetics and Genomics. An accurate, reliable, short runaround time and cost-effective method may be helpful in mass population screening for SMA. <b><i>Methods:</i></b> Multiplex ligation-dependent probe amplification (MLPA) is a gold standard to estimate the copy number variation (CNV) for <i>SMN1</i> and <i>SMN2</i> genes. In this study, we validated droplet digital polymerase chain reaction (ddPCR) for the determination of CNV for both <i>SMN1</i> and <i>SMN2</i> exon 7 for a diagnostic purpose. In total, 66 clinical samples were tested using ddPCR, and results were compared with the MLPA as a reference test. <b><i>Results:</i></b> For all samples, CNV for <i>SMN1</i> and <i>SMN2</i> exon 7 was consentaneous between ddPCR and MLPA test results (κ = 1.000, <i>p</i> &lt; 0.0001). In addition, ddPCR also showed a significant acceptable degree of test repeatability, coefficient of variation &lt; 4%. <b><i>Conclusion:</i></b> ddPCR is expected to be utilitarian for CNV detection for carrier screening and diagnosis of SMA. ddPCR test results for CNV detection for <i>SMN1</i>/<i>SMN2</i> exon 7 are concordant with the gold standard. ddPCR is a more cost-effective and time-saving diagnostic test for SMA than MLPA. Furthermore, it can be used for population-wide carrier screening for SMA.
genetics & heredity
What problem does this paper attempt to address?